JPWO2021171003A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021171003A5 JPWO2021171003A5 JP2022550813A JP2022550813A JPWO2021171003A5 JP WO2021171003 A5 JPWO2021171003 A5 JP WO2021171003A5 JP 2022550813 A JP2022550813 A JP 2022550813A JP 2022550813 A JP2022550813 A JP 2022550813A JP WO2021171003 A5 JPWO2021171003 A5 JP WO2021171003A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- optionally
- sequence
- lcdr1
- lcdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000003394 haemopoietic effect Effects 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Claims (30)
配列番号56、48~55、57~70、及び(図1の)配列A1~A23のいずれか1つと少なくとも80%の配列同一性を有する配列を含むCDR2、及び/または、
配列番号79、71~78、及び80~116のいずれか1つと少なくとも80%の配列同一性を有する配列を含むCDR1のうちの1つ以上を含む、抗ガンマ可変4(Vγ4)抗体またはその断片を、
Vγ4T細胞を含む細胞集団に投与することを含む、Vγ4T細胞を調節するex vivo方法。 CDR3 comprising a sequence having at least 80% sequence identity with any one of SEQ ID NOs: 10 , 2-9, and 11-47 ;
a CDR2 comprising a sequence having at least 80% sequence identity with any one of SEQ ID NOs: 56 , 48-55, 57-70, and sequences A1-A23 (of Figure 1), and/or
an anti-gamma variable 4 (Vγ4) antibody comprising one or more of CDR1 comprising a sequence having at least 80% sequence identity with any one of SEQ ID NOs: 79, 71-78, and 80-116; or The fragment,
An ex vivo method of modulating Vγ4T cells comprising administering to a cell population comprising Vγ4T cells.
配列番号102を有するLCDR1、(図1の)配列A9を有するLCDR2及び配列番号33を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号148または269を含む前記VL、
(b)配列番号86を有するHCDR1、配列番号63を有するHCDR2及び配列番号17を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号132を含む前記VHと、
配列番号109を有するLCDR1、(図1の)配列A16を有するLCDR2及び配列番号40を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号155または276を含む前記VL、
(c)配列番号73を有するHCDR1、配列番号50を有するHCDR2及び配列番号4を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号119を含む前記VHと、
配列番号96を有するLCDR1、(図1の)配列A3を有するLCDR2及び配列番号27を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号142または263を含む前記VL、
(d)配列番号83を有するHCDR1、配列番号60を有するHCDR2及び配列番号14を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号129を含む前記VHと、
配列番号106を有するLCDR1、(図1の)配列A13を有するLCDR2及び配列番号37を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号152または273を含む前記VL、
(e)配列番号84を有するHCDR1、配列番号61を有するHCDR2及び配列番号15を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号130を含む前記VHと、
配列番号107を有するLCDR1、(図1の)配列A14を有するLCDR2及び配列番号38を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号153または274を含む前記VL、
(f)配列番号88を有するHCDR1、配列番号65を有するHCDR2及び配列番号19を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号134を含む前記VHと、
配列番号111を有するLCDR1、(図1の)配列A18を有するLCDR2及び配列番号42を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号157または278を含む前記VL、
(g)配列番号92を有するHCDR1、配列番号69を有するHCDR2及び配列番号23を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号138を含む前記VHと、
配列番号115を有するLCDR1、(図1の)配列A22を有するLCDR2及び配列番号46を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号161または282を含む前記VL、
(h)配列番号71を有するHCDR1、配列番号48を有するHCDR2及び配列番号2を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号117を含む前記VHと、
配列番号94を有するLCDR1、(図1の)配列A1を有するLCDR2及び配列番号25を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号140または261を含む前記VL、
(i)配列番号72を有するHCDR1、配列番号49を有するHCDR2及び配列番号3を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号118を含む前記VHと、
配列番号95を有するLCDR1、(図1の)配列A2を有するLCDR2及び配列番号26を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号141または262を含む前記VL、
(j)配列番号74を有するHCDR1、配列番号51を有するHCDR2及び配列番号5を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号120を含む前記VHと、
配列番号97を有するLCDR1、(図1の)配列A4を有するLCDR2及び配列番号28を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号143または264を含む前記VL、
(k)配列番号75を有するHCDR1、配列番号52を有するHCDR2及び配列番号6を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号121を含む前記VHと、
配列番号98を有するLCDR1、(図1の)配列A5を有するLCDR2及び配列番号29を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号144または265を含む前記VL、
(l)配列番号76を有するHCDR1、配列番号53を有するHCDR2及び配列番号7を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号122を含む前記VHと、
配列番号99を有するLCDR1、(図1の)配列A6を有するLCDR2及び配列番号30を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号145または266を含む前記VL、
(m)配列番号77を有するHCDR1、配列番号54を有するHCDR2及び配列番号8を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号123を含む前記VHと、
配列番号100を有するLCDR1、(図1の)配列A7を有するLCDR2及び配列番号31を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号146または267を含む前記VL、
(n)配列番号78を有するHCDR1、配列番号55を有するHCDR2及び配列番号9を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号124を含む前記VHと、
配列番号101を有するLCDR1、(図1の)配列A8を有するLCDR2及び配列番号32を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号147または268を含む前記VL、
(o)配列番号80を有するHCDR1、配列番号57を有するHCDR2及び配列番号11を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号126を含む前記VHと、
配列番号103を有するLCDR1、(図1の)配列A10を有するLCDR2及び配列番号34を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号149または270を含む前記VL、
(p)配列番号81を有するHCDR1、配列番号58を有するHCDR2及び配列番号12を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号127を含む前記VHと、
配列番号104を有するLCDR1、(図1の)配列A11を有するLCDR2及び配列番号35を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号150または271を含む前記VL、
(q)配列番号82を有するHCDR1、配列番号59を有するHCDR2及び配列番号13を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号128を含む前記VHと、
配列番号105を有するLCDR1、(図1の)配列A12を有するLCDR2及び配列番号36を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号151または272を含む前記VL、
(r)配列番号85を有するHCDR1、配列番号62を有するHCDR2及び配列番号16を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号131を含む前記VHと、
配列番号108を有するLCDR1、(図1の)配列A15を有するLCDR2及び配列番号39を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号154または275を含む前記VL、
(s)配列番号87を有するHCDR1、配列番号64を有するHCDR2及び配列番号18を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号133を含む前記VHと、
配列番号110を有するLCDR1、(図1の)配列A17を有するLCDR2及び配列番号41を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号156または277を含む前記VL、
(t)配列番号89を有するHCDR1、配列番号66を有するHCDR2及び配列番号20を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号135を含む前記VHと、
配列番号112を有するLCDR1、(図1の)配列A19を有するLCDR2及び配列番号43を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号158または279を含む前記VL、
(u)配列番号90を有するHCDR1、配列番号67を有するHCDR2及び配列番号21を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号136を含む前記VHと、
配列番号113を有するLCDR1、(図1の)配列A20を有するLCDR2及び配列番号44を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号159または280を含む前記VL、
(v)配列番号91を有するHCDR1、配列番号68を有するHCDR2及び配列番号22を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号137を含む前記VHと、
配列番号114を有するLCDR1、(図1の)配列A21を有するLCDR2及び配列番号45を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号160または281を含む前記VL、
及び/または、
(w)配列番号93を有するHCDR1、配列番号70を有するHCDR2及び配列番号24を有するHCDR3を含むVHであって、任意選択で前記VHは配列番号139を含む前記VHと、
配列番号116を有するLCDR1、(図1の)配列A23を有するLCDR2及び配列番号47を有するLCDR3を含むVLであって、任意選択で前記VLは配列番号162または283を含む前記VL、のうちの1つ以上を含む抗ガンマ可変4(Vγ4)抗体またはその断片を、
Vγ4T細胞を含む細胞集団に投与することを含む、Vγ4T細胞を調節するex vivo方法。 (a) a VH comprising HCDR1 having SEQ ID NO: 79, HCDR2 having SEQ ID NO: 56 and HCDR3 having SEQ ID NO: 10, optionally said VH comprising SEQ ID NO: 125;
a VL comprising LCDR1 with SEQ ID NO: 102, LCDR2 with sequence A9 (of FIG. 1) and LCDR3 with SEQ ID NO: 33, optionally said VL comprising SEQ ID NO: 148 or 269;
(b) a VH comprising HCDR1 having SEQ ID NO: 86, HCDR2 having SEQ ID NO: 63 and HCDR3 having SEQ ID NO: 17, optionally said VH comprising SEQ ID NO: 132;
a VL comprising LCDR1 with SEQ ID NO: 109, LCDR2 with sequence A16 (of FIG. 1) and LCDR3 with SEQ ID NO: 40, optionally said VL comprising SEQ ID NO: 155 or 276;
(c) a VH comprising HCDR1 having SEQ ID NO: 73, HCDR2 having SEQ ID NO: 50 and HCDR3 having SEQ ID NO: 4, optionally said VH comprising SEQ ID NO: 119;
a VL comprising LCDR1 with SEQ ID NO: 96, LCDR2 with sequence A3 (of FIG. 1) and LCDR3 with SEQ ID NO: 27, optionally said VL comprising SEQ ID NO: 142 or 263;
(d) a VH comprising HCDR1 having SEQ ID NO: 83, HCDR2 having SEQ ID NO: 60 and HCDR3 having SEQ ID NO: 14, optionally said VH comprising SEQ ID NO: 129;
a VL comprising LCDR1 with SEQ ID NO: 106, LCDR2 with sequence A13 (of FIG. 1) and LCDR3 with SEQ ID NO: 37, optionally said VL comprising SEQ ID NO: 152 or 273;
(e) a VH comprising HCDR1 having SEQ ID NO: 84, HCDR2 having SEQ ID NO: 61 and HCDR3 having SEQ ID NO: 15, optionally said VH comprising SEQ ID NO: 130;
a VL comprising LCDR1 with SEQ ID NO: 107, LCDR2 with sequence A14 (of FIG. 1) and LCDR3 with SEQ ID NO: 38, optionally said VL comprising SEQ ID NO: 153 or 274;
(f) a VH comprising HCDR1 having SEQ ID NO: 88, HCDR2 having SEQ ID NO: 65 and HCDR3 having SEQ ID NO: 19, optionally said VH comprising SEQ ID NO: 134;
a VL comprising LCDR1 with SEQ ID NO: 111, LCDR2 with sequence A18 (of FIG. 1) and LCDR3 with SEQ ID NO: 42, optionally said VL comprising SEQ ID NO: 157 or 278;
(g) a VH comprising HCDR1 having SEQ ID NO: 92, HCDR2 having SEQ ID NO: 69 and HCDR3 having SEQ ID NO: 23, optionally said VH comprising SEQ ID NO: 138;
a VL comprising LCDR1 with SEQ ID NO: 115, LCDR2 with sequence A22 (of FIG. 1) and LCDR3 with SEQ ID NO: 46, optionally said VL comprising SEQ ID NO: 161 or 282;
(h) a VH comprising HCDR1 having SEQ ID NO: 71, HCDR2 having SEQ ID NO: 48 and HCDR3 having SEQ ID NO: 2, optionally said VH comprising SEQ ID NO: 117;
a VL comprising LCDR1 with SEQ ID NO: 94, LCDR2 with sequence A1 (of FIG. 1) and LCDR3 with SEQ ID NO: 25, optionally said VL comprising SEQ ID NO: 140 or 261;
(i) a VH comprising HCDR1 having SEQ ID NO: 72, HCDR2 having SEQ ID NO: 49 and HCDR3 having SEQ ID NO: 3, optionally said VH comprising SEQ ID NO: 118;
a VL comprising LCDR1 with SEQ ID NO: 95, LCDR2 with sequence A2 (of FIG. 1) and LCDR3 with SEQ ID NO: 26, optionally said VL comprising SEQ ID NO: 141 or 262;
(j) a VH comprising HCDR1 having SEQ ID NO: 74, HCDR2 having SEQ ID NO: 51 and HCDR3 having SEQ ID NO: 5, optionally said VH comprising SEQ ID NO: 120;
a VL comprising LCDR1 with SEQ ID NO: 97, LCDR2 with sequence A4 (of FIG. 1) and LCDR3 with SEQ ID NO: 28, optionally said VL comprising SEQ ID NO: 143 or 264;
(k) a VH comprising HCDR1 having SEQ ID NO: 75, HCDR2 having SEQ ID NO: 52 and HCDR3 having SEQ ID NO: 6, optionally said VH comprising SEQ ID NO: 121;
a VL comprising LCDR1 with SEQ ID NO: 98, LCDR2 with sequence A5 (of FIG. 1) and LCDR3 with SEQ ID NO: 29, optionally said VL comprising SEQ ID NO: 144 or 265;
(l) a VH comprising HCDR1 having SEQ ID NO: 76, HCDR2 having SEQ ID NO: 53 and HCDR3 having SEQ ID NO: 7, optionally said VH comprising SEQ ID NO: 122;
a VL comprising LCDR1 with SEQ ID NO: 99, LCDR2 with sequence A6 (of FIG. 1) and LCDR3 with SEQ ID NO: 30, optionally said VL comprising SEQ ID NO: 145 or 266;
(m) a VH comprising HCDR1 with SEQ ID NO: 77, HCDR2 with SEQ ID NO: 54 and HCDR3 with SEQ ID NO: 8, optionally said VH comprising SEQ ID NO: 123;
a VL comprising LCDR1 with SEQ ID NO: 100, LCDR2 with sequence A7 (of FIG. 1) and LCDR3 with SEQ ID NO: 31, optionally said VL comprising SEQ ID NO: 146 or 267;
(n) a VH comprising HCDR1 having SEQ ID NO: 78, HCDR2 having SEQ ID NO: 55 and HCDR3 having SEQ ID NO: 9, optionally said VH comprising SEQ ID NO: 124;
a VL comprising LCDR1 with SEQ ID NO: 101, LCDR2 with sequence A8 (of FIG. 1) and LCDR3 with SEQ ID NO: 32, optionally said VL comprising SEQ ID NO: 147 or 268;
(o) a VH comprising HCDR1 having SEQ ID NO: 80, HCDR2 having SEQ ID NO: 57 and HCDR3 having SEQ ID NO: 11, optionally said VH comprising SEQ ID NO: 126;
a VL comprising LCDR1 with SEQ ID NO: 103, LCDR2 with sequence A10 (of FIG. 1) and LCDR3 with SEQ ID NO: 34, optionally said VL comprising SEQ ID NO: 149 or 270;
(p) a VH comprising HCDR1 having SEQ ID NO: 81, HCDR2 having SEQ ID NO: 58 and HCDR3 having SEQ ID NO: 12, optionally said VH comprising SEQ ID NO: 127;
a VL comprising LCDR1 with SEQ ID NO: 104, LCDR2 with sequence A11 (of FIG. 1) and LCDR3 with SEQ ID NO: 35, optionally said VL comprising SEQ ID NO: 150 or 271;
(q) a VH comprising HCDR1 having SEQ ID NO: 82, HCDR2 having SEQ ID NO: 59 and HCDR3 having SEQ ID NO: 13, optionally said VH comprising SEQ ID NO: 128;
a VL comprising LCDR1 with SEQ ID NO: 105, LCDR2 with sequence A12 (of FIG. 1) and LCDR3 with SEQ ID NO: 36, optionally said VL comprising SEQ ID NO: 151 or 272;
(r) a VH comprising HCDR1 with SEQ ID NO: 85, HCDR2 with SEQ ID NO: 62 and HCDR3 with SEQ ID NO: 16, optionally said VH comprising SEQ ID NO: 131;
a VL comprising LCDR1 with SEQ ID NO: 108, LCDR2 with sequence A15 (of FIG. 1) and LCDR3 with SEQ ID NO: 39, optionally said VL comprising SEQ ID NO: 154 or 275;
(s) a VH comprising HCDR1 with SEQ ID NO: 87, HCDR2 with SEQ ID NO: 64 and HCDR3 with SEQ ID NO: 18, optionally said VH comprising SEQ ID NO: 133;
a VL comprising LCDR1 with SEQ ID NO: 110, LCDR2 with sequence A17 (of FIG. 1) and LCDR3 with SEQ ID NO: 41, optionally said VL comprising SEQ ID NO: 156 or 277;
(t) a VH comprising HCDR1 having SEQ ID NO: 89, HCDR2 having SEQ ID NO: 66 and HCDR3 having SEQ ID NO: 20, optionally said VH comprising SEQ ID NO: 135;
a VL comprising LCDR1 with SEQ ID NO: 112, LCDR2 with sequence A19 (of FIG. 1) and LCDR3 with SEQ ID NO: 43, optionally said VL comprising SEQ ID NO: 158 or 279;
(u) a VH comprising HCDR1 having SEQ ID NO: 90, HCDR2 having SEQ ID NO: 67 and HCDR3 having SEQ ID NO: 21, optionally said VH comprising SEQ ID NO: 136;
a VL comprising LCDR1 with SEQ ID NO: 113, LCDR2 with sequence A20 (of FIG. 1) and LCDR3 with SEQ ID NO: 44, optionally said VL comprising SEQ ID NO: 159 or 280;
(v) a VH comprising HCDR1 having SEQ ID NO: 91, HCDR2 having SEQ ID NO: 68 and HCDR3 having SEQ ID NO: 22, optionally said VH comprising SEQ ID NO: 137;
a VL comprising LCDR1 with SEQ ID NO: 114, LCDR2 with sequence A21 (of FIG. 1) and LCDR3 with SEQ ID NO: 45, optionally said VL comprising SEQ ID NO: 160 or 281;
and/or
(w) a VH comprising HCDR1 having SEQ ID NO: 93, HCDR2 having SEQ ID NO: 70 and HCDR3 having SEQ ID NO: 24, optionally said VH comprising SEQ ID NO: 139;
A VL comprising LCDR1 with SEQ ID NO: 116, LCDR2 with sequence A23 (of FIG. 1) and LCDR3 with SEQ ID NO: 47, optionally said VL comprising SEQ ID NO: 162 or 283. an anti-gamma variable 4 (Vγ4) antibody or fragment thereof comprising one or more
An ex vivo method of modulating Vγ4T cells comprising administering to a cell population comprising Vγ4T cells.
(i)scFvまたは完全長抗体、及び/または、
(ii)ヒト抗体もしくはその断片である、請求項1~15のいずれ一項に記載の方法。 The anti-Vγ4 antibody or fragment thereof is
(i) scFv or full length antibody, and/or
(ii) The method according to any one of claims 1 to 15, which is a human antibody or a fragment thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2002581.3A GB202002581D0 (en) | 2020-02-24 | 2020-02-24 | Novel antibodies |
GB2002581.3 | 2020-02-24 | ||
PCT/GB2021/050460 WO2021171003A1 (en) | 2020-02-24 | 2021-02-24 | Ex vivo gamma delta t cell populations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023514437A JP2023514437A (en) | 2023-04-05 |
JPWO2021171003A5 true JPWO2021171003A5 (en) | 2024-01-30 |
Family
ID=70108379
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022550778A Pending JP2023516925A (en) | 2020-02-24 | 2021-02-24 | novel antibody |
JP2022550813A Pending JP2023514437A (en) | 2020-02-24 | 2021-02-24 | EX VIVO gamma delta T cell population |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022550778A Pending JP2023516925A (en) | 2020-02-24 | 2021-02-24 | novel antibody |
Country Status (16)
Country | Link |
---|---|
US (2) | US20230090901A1 (en) |
EP (2) | EP4110387A1 (en) |
JP (2) | JP2023516925A (en) |
KR (2) | KR20220164473A (en) |
CN (2) | CN115697401A (en) |
AU (2) | AU2021228266A1 (en) |
BR (2) | BR112022016894A2 (en) |
CA (2) | CA3172340A1 (en) |
CL (1) | CL2022002296A1 (en) |
CO (2) | CO2022013542A2 (en) |
EC (1) | ECSP22074030A (en) |
GB (1) | GB202002581D0 (en) |
IL (2) | IL295852A (en) |
MX (2) | MX2022010383A (en) |
PE (1) | PE20230438A1 (en) |
WO (2) | WO2021171003A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
CN114514245A (en) * | 2019-08-16 | 2022-05-17 | 伽马三角洲疗法有限公司 | Novel anti-TCR delta variable 1 antibodies |
-
2020
- 2020-02-24 GB GBGB2002581.3A patent/GB202002581D0/en not_active Ceased
-
2021
- 2021-02-24 EP EP21709758.3A patent/EP4110387A1/en active Pending
- 2021-02-24 CA CA3172340A patent/CA3172340A1/en active Pending
- 2021-02-24 US US17/801,786 patent/US20230090901A1/en active Pending
- 2021-02-24 EP EP21709757.5A patent/EP4110813A1/en active Pending
- 2021-02-24 WO PCT/GB2021/050460 patent/WO2021171003A1/en unknown
- 2021-02-24 JP JP2022550778A patent/JP2023516925A/en active Pending
- 2021-02-24 CA CA3168973A patent/CA3168973A1/en active Pending
- 2021-02-24 BR BR112022016894A patent/BR112022016894A2/en unknown
- 2021-02-24 US US17/904,890 patent/US20230159638A1/en active Pending
- 2021-02-24 AU AU2021228266A patent/AU2021228266A1/en active Pending
- 2021-02-24 MX MX2022010383A patent/MX2022010383A/en unknown
- 2021-02-24 CN CN202180028136.1A patent/CN115697401A/en active Pending
- 2021-02-24 MX MX2022010239A patent/MX2022010239A/en unknown
- 2021-02-24 IL IL295852A patent/IL295852A/en unknown
- 2021-02-24 BR BR112022016671A patent/BR112022016671A2/en unknown
- 2021-02-24 PE PE2022001812A patent/PE20230438A1/en unknown
- 2021-02-24 WO PCT/GB2021/050459 patent/WO2021171002A1/en active Application Filing
- 2021-02-24 CN CN202180030584.5A patent/CN115461369A/en active Pending
- 2021-02-24 AU AU2021225390A patent/AU2021225390A1/en active Pending
- 2021-02-24 JP JP2022550813A patent/JP2023514437A/en active Pending
- 2021-02-24 KR KR1020227029501A patent/KR20220164473A/en unknown
- 2021-02-24 KR KR1020227033455A patent/KR20220145894A/en unknown
- 2021-02-24 IL IL295696A patent/IL295696A/en unknown
-
2022
- 2022-08-23 CL CL2022002296A patent/CL2022002296A1/en unknown
- 2022-09-21 CO CONC2022/0013542A patent/CO2022013542A2/en unknown
- 2022-09-22 EC ECSENADI202274030A patent/ECSP22074030A/en unknown
- 2022-09-22 CO CONC2022/0013633A patent/CO2022013633A2/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020520665A5 (en) | ||
JP6650537B2 (en) | Anti-CTLA-4 antibody | |
RU2715628C2 (en) | Antibodies to pd-1 | |
AU2009224690B2 (en) | Agent for treating disease | |
TW202003580A (en) | Compositions and methods for enhancing the killing of target cells by NK cells | |
RU2375375C2 (en) | Humanised ahth-cd4 antibody with immunosuppressive properties | |
CN109563170B (en) | anti-GITR antibodies and uses thereof | |
US20050176028A1 (en) | Deimmunized binding molecules to CD3 | |
CN109328074A (en) | Chimeric antigen and T cell receptor and the method used | |
RU2019134352A (en) | NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH THE ABILITY TO BIND SPECIFICALLY WITH CD40 AND FAP | |
JP2022169504A5 (en) | ||
US20240052046A1 (en) | Il2rbeta/common gamma chain antibodies | |
US20120027759A1 (en) | Methods of enhancing t cell responsiveness | |
JP2022513778A (en) | Chimeric antigen receptor and T cell receptor and how to use | |
RU2007139953A (en) | ANTIBODIES TO CCR5 AND THEIR APPLICATION | |
CA2148712A1 (en) | Peripheralization of hematopoietic stem cells | |
JPH07246091A (en) | Method for selective production of hybridoma cell strain for producing monoclonal antibody having high cytotoxicity against human cd16-antigen and method for production of cd30-hrs-3-antibody for treating double specific monoclonal antibody and human tumor using said monoclonal antibody | |
JPH10182487A (en) | 2-or 3-specific antibody for antitumor immune induction | |
EP1450828A2 (en) | In situ immunization | |
CN105251004A (en) | Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis | |
JP2020528744A (en) | Methods and Compositions for Chimeric Antigen Receptors Targeting Cancer Cells | |
RU2010119450A (en) | ANTIBODY AGAINST BST2 | |
CA3117759A1 (en) | Cll1-targeting antibody and application thereof | |
Bruno et al. | The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases | |
JP2021500916A5 (en) |